PL3655778T3 - Agryna jako marker raka endometrium - Google Patents
Agryna jako marker raka endometriumInfo
- Publication number
- PL3655778T3 PL3655778T3 PL18749741.7T PL18749741T PL3655778T3 PL 3655778 T3 PL3655778 T3 PL 3655778T3 PL 18749741 T PL18749741 T PL 18749741T PL 3655778 T3 PL3655778 T3 PL 3655778T3
- Authority
- PL
- Poland
- Prior art keywords
- agrin
- marker
- endometrial cancer
- endometrial
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Genetics & Genomics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Reproductive Health (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382483 | 2017-07-21 | ||
| PCT/EP2018/069841 WO2019016400A1 (en) | 2017-07-21 | 2018-07-20 | CTNB1 AS A MARKER FOR CANCER OF THE ENDOMETER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3655778T3 true PL3655778T3 (pl) | 2023-09-18 |
Family
ID=59558350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18749741.7T PL3655778T3 (pl) | 2017-07-21 | 2018-07-20 | Agryna jako marker raka endometrium |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200264183A1 (pl) |
| EP (2) | EP4220171A3 (pl) |
| JP (2) | JP7421218B2 (pl) |
| CN (2) | CN117288953A (pl) |
| AU (2) | AU2018303249B2 (pl) |
| BR (1) | BR112020000926A2 (pl) |
| CA (1) | CA3070041A1 (pl) |
| DK (1) | DK3655778T3 (pl) |
| ES (1) | ES2953011T3 (pl) |
| FI (1) | FI3655778T3 (pl) |
| PL (1) | PL3655778T3 (pl) |
| PT (1) | PT3655778T (pl) |
| WO (1) | WO2019016400A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859872A (zh) * | 2016-03-08 | 2016-08-17 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| GB202103200D0 (en) * | 2021-03-08 | 2021-04-21 | Terasom S R O | Lung Cancer diagnosis |
| JP2024525939A (ja) * | 2021-07-23 | 2024-07-12 | フンダシオ オスピタル ウニベルシタリ バル デブロン-インスティテュート デ レセルカ | 子宮内膜がんのバイオマーカー |
| CN113493839A (zh) * | 2021-09-06 | 2021-10-12 | 北京泱深生物信息技术有限公司 | 基因标志物组合在诊断子宫内膜癌中的应用 |
| JP2023156159A (ja) * | 2022-04-12 | 2023-10-24 | テオリアサイエンス株式会社 | がんリスクの試験方法 |
| CN117524320B (zh) * | 2023-10-30 | 2024-11-26 | 重庆医科大学 | 基于tpis、enoa、ppib泪液标志物的妊娠鉴别人工智能模型构建方法及试剂盒 |
| WO2025255460A1 (en) * | 2024-06-06 | 2025-12-11 | Ampa Biosciences Inc. | Methods for early cancer detection using exosomal pcna biomarkers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE388694B (sv) | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
| US4235601A (en) | 1979-01-12 | 1980-11-25 | Thyroid Diagnostics, Inc. | Test device and method for its use |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4442204A (en) | 1981-04-10 | 1984-04-10 | Miles Laboratories, Inc. | Homogeneous specific binding assay device and preformed complex method |
| US5208535A (en) | 1990-12-28 | 1993-05-04 | Research Development Corporation Of Japan | Mr position detecting device |
| US20050182656A1 (en) * | 1999-05-28 | 2005-08-18 | Morey Fred R. | On-line prescription service system and method |
| EP1711618B1 (en) * | 2003-12-23 | 2010-08-04 | Mount Sinai Hospital Corporation | Methods for detecting markers associated with endometrial disease or phase |
| US7657521B2 (en) * | 2005-04-15 | 2010-02-02 | General Electric Company | System and method for parsing medical data |
| US8329399B2 (en) * | 2006-10-27 | 2012-12-11 | Siu K W Michael | Endometrial biomarkers |
| KR20100015883A (ko) | 2007-03-23 | 2010-02-12 | 더 트랜스내셔날 게노믹스 리서치 인스티튜트 | 자궁내막암 및 전암을 진단,분류 및 치료하는 방법 |
| US20110256560A1 (en) * | 2008-10-20 | 2011-10-20 | University Health Network | Methods and compositions for the detection of ovarian cancer |
| ES2654340T3 (es) * | 2009-07-24 | 2018-02-13 | Geadic Biotec, Aie. | Marcadores para cáncer endometrial |
| EP2631657A1 (en) | 2012-02-25 | 2013-08-28 | Neurotune AG | Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin |
| WO2013152989A2 (en) * | 2012-04-10 | 2013-10-17 | Eth Zurich | Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer |
| US20140121127A1 (en) | 2012-10-31 | 2014-05-01 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Diagnosis of Ovarian Cancer |
| MX368099B (es) * | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
| WO2017173250A1 (en) * | 2016-03-31 | 2017-10-05 | The University Of North Carolina At Chapel Hill | Methods and compositions for sirt1 expression as a marker for endometriosis and subfertility |
| AU2017260806B9 (en) * | 2016-05-04 | 2023-07-20 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Markers of endometrial cancer |
-
2018
- 2018-07-20 CN CN202311246811.5A patent/CN117288953A/zh active Pending
- 2018-07-20 PT PT187497417T patent/PT3655778T/pt unknown
- 2018-07-20 CA CA3070041A patent/CA3070041A1/en active Pending
- 2018-07-20 WO PCT/EP2018/069841 patent/WO2019016400A1/en not_active Ceased
- 2018-07-20 US US16/632,739 patent/US20200264183A1/en not_active Abandoned
- 2018-07-20 ES ES18749741T patent/ES2953011T3/es active Active
- 2018-07-20 DK DK18749741.7T patent/DK3655778T3/da active
- 2018-07-20 CN CN201880049974.5A patent/CN111065925B/zh active Active
- 2018-07-20 FI FIEP18749741.7T patent/FI3655778T3/fi active
- 2018-07-20 PL PL18749741.7T patent/PL3655778T3/pl unknown
- 2018-07-20 JP JP2020502167A patent/JP7421218B2/ja active Active
- 2018-07-20 BR BR112020000926-1A patent/BR112020000926A2/pt unknown
- 2018-07-20 EP EP23151625.3A patent/EP4220171A3/en active Pending
- 2018-07-20 AU AU2018303249A patent/AU2018303249B2/en active Active
- 2018-07-20 EP EP18749741.7A patent/EP3655778B1/en active Active
-
2023
- 2023-06-15 US US18/210,463 patent/US20240011994A1/en not_active Abandoned
- 2023-08-10 JP JP2023131042A patent/JP2023164819A/ja active Pending
-
2025
- 2025-05-26 AU AU2025203864A patent/AU2025203864A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4220171A2 (en) | 2023-08-02 |
| CN111065925B (zh) | 2023-10-20 |
| CN111065925A (zh) | 2020-04-24 |
| ES2953011T3 (es) | 2023-11-07 |
| CN117288953A (zh) | 2023-12-26 |
| AU2018303249B2 (en) | 2025-02-27 |
| JP7421218B2 (ja) | 2024-01-24 |
| AU2018303249A1 (en) | 2020-02-06 |
| JP2023164819A (ja) | 2023-11-14 |
| US20200264183A1 (en) | 2020-08-20 |
| EP3655778A1 (en) | 2020-05-27 |
| JP2020527711A (ja) | 2020-09-10 |
| EP4220171A3 (en) | 2023-10-25 |
| EP3655778B1 (en) | 2023-06-07 |
| FI3655778T3 (fi) | 2023-08-09 |
| PT3655778T (pt) | 2023-08-18 |
| CA3070041A1 (en) | 2019-01-24 |
| DK3655778T3 (da) | 2023-07-31 |
| US20240011994A1 (en) | 2024-01-11 |
| BR112020000926A2 (pt) | 2020-07-21 |
| WO2019016400A1 (en) | 2019-01-24 |
| AU2025203864A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294211B2 (en) | Mark location | |
| PL3655778T3 (pl) | Agryna jako marker raka endometrium | |
| IL261486A (en) | ENT device for use with one hand | |
| ZA201805842B (en) | Chromogranin a as a marker for bladder cancer | |
| PL3593139T3 (pl) | Biomarkery nowotworowe | |
| EP3243882A4 (en) | Ink for surgical marker | |
| GB2558123B (en) | Roller-ball paint marker | |
| EP3415863A4 (en) | MARKER | |
| GB202001931D0 (en) | Zero distance tool | |
| GB2570100B (en) | Tool positioning | |
| PT3452829T (pt) | Perm como marcador de cancro endometrial | |
| IL254352B (en) | Antenna for otolaryngology | |
| EP3424671A4 (en) | MARKER PEN | |
| GB2565225B (en) | Positioning Tool | |
| EP3540369A4 (en) | MARKER | |
| EP3540367A4 (en) | MARKER | |
| GB2576994B (en) | Road marker placement apparatus | |
| EP3470771A4 (en) | MARKER PEN | |
| EP3421927A4 (en) | MARKER PEN | |
| GB201820629D0 (en) | Marker | |
| GB201720082D0 (en) | Marker airbrush | |
| GB2568457B (en) | Surface marker | |
| GB201805721D0 (en) | Lit marker | |
| AU2017904023A0 (en) | Marker | |
| GB201804618D0 (en) | Novel Marker |